id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0936-0010,FDA,FDA-2022-E-0936,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-01-17T05:00:00Z,2025,1,2025-01-17T05:00:00Z,,2025-01-17T15:15:31Z,,0,0,09000064868cae7f
FDA-2022-E-0936-0007,FDA,FDA-2022-E-0936,Interim Extension Letter,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T20:50:03Z,,0,0,09000064863e62e2
FDA-2022-E-0936-0008,FDA,FDA-2022-E-0936,Letter from U.S. Patent and Trademark Office to McCarter & English LLP,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T20:50:18Z,,0,0,090000648661359d
FDA-2022-E-0936-0009,FDA,FDA-2022-E-0936,Requirement for Information,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T20:50:27Z,,0,0,0900006486613a70
FDA-2022-E-0936-0006,FDA,FDA-2022-E-0936,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T21:48:32Z,,0,0,09000064863ae6f0
FDA-2022-E-0936-0005,FDA,FDA-2022-E-0936,Determination of Regulatory Review Period for Purposes of Patent Extension; ZOKINVY,Notice,Determinations,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,2024-06-25T03:59:59Z,2023-12-27T15:24:10Z,2023-28511,0,0,090000648635c012
FDA-2022-E-0936-0004,FDA,FDA-2022-E-0936,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,,2022-11-09T21:52:41Z,,0,0,09000064854a0144
FDA-2022-E-0936-0003,FDA,FDA-2022-E-0936,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-28T04:00:00Z,2022,9,2022-09-28T04:00:00Z,,2022-09-28T20:08:24Z,,0,0,090000648537b7d5
FDA-2022-E-0936-0001,FDA,FDA-2022-E-0936,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-05-27T04:00:00Z,2022,5,2022-05-27T04:00:00Z,,2022-05-27T18:48:48Z,,0,0,09000064850ff6f6
FDA-2022-E-0936-0002,FDA,FDA-2022-E-0936,"Patent Extension Application from McCarter & English LLP (on behalf of The Regents of the University of Michigan, Progeria Research Foundation, Inc. and The University of North Carolina at Chapel Hill)",Other,Application,2022-05-27T04:00:00Z,2022,5,2022-05-27T04:00:00Z,,2022-05-27T18:48:54Z,,0,0,09000064850ff6f8